Skip to main content
main-content

08-11-2017 | ACR/ARHP 2017 | Video

Expert commentary: The ABILITY-3 trial

Walter Maksymowych comments on the ABILITY-3 trial results showing that continued adalimumab treatment is important for the maintenance of remission among patients with nonradiographic axial spondyloarthritis.

Read the accompanying news story